脑转移瘤三分配立体定向放射外科治疗后脑剂量-体积耐受性与放射性坏死的预测因素:一项大型单中心分析
该单中心回顾性研究分析2015至2021年接受3次分割立体定向放射外科(SRS)的434例患者共539个疗程、2518个病灶,中位SRS剂量24 Gy,中位随访7.9个月。93例(17.2%)和123个病灶(4.9%)发生任何级别放射性坏死(RN),42例(7.8%)和57个病灶(2.3%)发生≥3级RN(G3RN)。V20和V23分别是最佳预测任何级别RN和G3RN的剂量学参数,V23<15 cc与G3RN风险<5%相关,G3RN的TD50为31.4 Gy(95%CI 27.8-35.1 Gy)。
要点
- 3次分割SRS后G3RN见于7.8%的患者和2.3%的病灶。
- V20和V23分别是预测任何级别RN和G3RN的最佳剂量学参数。
- V23<15 cc与G3RN风险<5%相关,G3RN的TD50为31.4 Gy。
核心结论
- 在接受3次分割SRS的患者中,G3RN见于7.8%的患者和2.3%的病灶。
- V20和V23是与RN相关的最稳健剂量学参数。
- 需要进一步研究评估分次SRS与单次SRS患者的结局和RN。
研究设计与样本
- 单中心回顾性分析,纳入2015至2021年接受基于直线加速器的3次分割SRS的434例患者共539个疗程、2518个病灶。
- 主要终点G3RN定义为严重症状伴磁共振成像灌注证据和/或活检证实的坏死。
- 对每个靶病灶周围组织体积进行勾画并记录体积剂量,采用逻辑回归和改良Lyman-Kutcher-Burman模型进行正常组织并发症概率建模。
主要发现
- 中位SRS剂量24 Gy,中位随访7.9个月,中位总生存9个月。
- 93例(17.2%)和123个病灶(4.9%)发生任何级别RN,42例(7.8%)和57个病灶(2.3%)发生G3RN。
- 逻辑回归显示V20和V23分别是最佳预测任何级别RN和G3RN的参数,V20为4 cc、10 cc、20 cc分别与任何级别RN风险<5%、<7.5%、<10%相关,V23<15 cc与G3RN风险<5%相关。
- 对G3RN的Lyman-Kutcher-Burman模型约束优化得到TD50为31.4 Gy(95%CI 27.8-35.1 Gy)。
关键数值与推荐
- V20为4 cc与任何级别RN风险<5%相关。
- V20为10 cc与任何级别RN风险<7.5%相关。
- V20为20 cc与任何级别RN风险<10%相关。
- V23<15 cc与G3RN风险<5%相关。
- G3RN的TD50为31.4 Gy(95%CI 27.8-35.1 Gy)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为单中心回顾性研究。
- 原文结论指出需要进一步研究评估分次SRS与单次SRS患者的结局和RN。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiosurgery (SRS) is the current standard of care in patients with brain metastases and controlled extracranial disease. Radiation necrosis (RN) is the dose-limiting side effect of SRS, but the dose constraints especially for fractionated SRS remain poorly defined. We assessed the risk of RN after 3-fraction SRS with a goal to identify specific dose-volume constraints associated with grade 3 or higher RN (G3RN). METHODS AND MATERIALS: A single-institutional retrospective review of patients treated with 3-fraction SRS was performed. The primary endpoint was G3RN, which was defined as severe symptoms with evidence of necrosis on magnetic resonance imaging with perfusion and/or biopsy confirmation. Tissue volume around each target lesion was contoured, and volumetric doses per lesion were recorded. Logistic regression models were used to estimate the relationship between RN and each volumetric dose, and normal tissue complication probability modeling was performed using a modified Lyman-Kutcher-Burman model. RESULTS: From 2015 to 2021, 434 patients underwent 539 courses of linear accelerator-based SRS; 2518 lesions were treated. Median SRS dose was 24 Gy. Median follow-up after SRS was 7.9 months, and the median overall survival was 9 months. A total of 93 patients (17.2%) and 123 lesions (4.9%) developed any RN. Forty-two patients (7.8%) and 57 lesions (2.3%) developed G3RN. On logistic regression, V20 and V23 were best predictors of any grade RN and G3RN, respectively, with cutoff values of 4 cc, 10 cc, and 20 cc associated with <5%, <7.5%, and <10% risk of any RN, respectively, and V23 < 15 cc associated with <5% risk of G3RN. With constrained optimization of the normal tissue complication probability Lyman-Kutcher-Burman model for G3RN, we obtained a TD50 (uniform dose resulting in a 50% complication risk) of 31.4 Gy (95% CI, 27.8-35.1 Gy). CONCLUSIONS: In patients receiving 3-fraction SRS, G3RN was seen in 7.8% of patients, and 2.3% of the lesions were treated. V20 and V23 were the most robust dosimetric parameters associated with RN. Further studies evaluating the outcomes and RN in patients treated with fractionated SRS compared with single-fraction SRS are warranted.
引用
- Upadhyay R, Ayan AS, Jain S, et al. Dose-Volume Tolerance of the Brain and Predictors of Radiation Necrosis After 3-Fraction Radiosurgery for Brain Metastases: A Large Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2023. PMID: 37574170. doi:10.1016/j.ijrobp.2023.07.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。